Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112918 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,451
- Enrollment target
NCT00112918 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 3,451 participants.
The verdict
NCT00112918, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,451 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab (Bv) may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer in adjuvant setting. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens with or without bevacizumab to compare how well they work in treating patients who have undergone surgery for high risk stage II or stage III colon cancer.
Interventions
- DRUG Capecitabine
- DRUG 5-Fluorouracil (5-FU)
- DRUG Oxaliplatin
- BIOLOGICAL Bevacizumab
- DRUG Leucovorin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,451 participants |
| Start Date | 2004-12 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112918
The ClinicalTrials.gov registry entry for NCT00112918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,451 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT00112918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112918 about?
NCT00112918 is a clinical study titled "Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and sprea...
What is the current status of trial NCT00112918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,451 participants. The study started on 2004-12. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00112918?
The interventions under investigation include: Capecitabine (DRUG), 5-Fluorouracil (5-FU) (DRUG), Oxaliplatin (DRUG), Bevacizumab (BIOLOGICAL), Leucovorin calcium (DRUG).
Who is sponsoring clinical trial NCT00112918?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.